MX2022000725A - Anticuerpos potenciadores del factor h y usos de estos. - Google Patents

Anticuerpos potenciadores del factor h y usos de estos.

Info

Publication number
MX2022000725A
MX2022000725A MX2022000725A MX2022000725A MX2022000725A MX 2022000725 A MX2022000725 A MX 2022000725A MX 2022000725 A MX2022000725 A MX 2022000725A MX 2022000725 A MX2022000725 A MX 2022000725A MX 2022000725 A MX2022000725 A MX 2022000725A
Authority
MX
Mexico
Prior art keywords
antibodies
factor
fragments
nucleic acids
complement activation
Prior art date
Application number
MX2022000725A
Other languages
English (en)
Inventor
Sridhar Govindarajan
Taco Willem Kuijpers
Diana Wouters
Maria Clara Brouwer
Richard Benjamin Pouw
Scott Lauder
Tom Purcell
Taede Rispens
Ilse Jongerius
Gillian Dekkers
Original Assignee
Gemini Therapeutics Sub Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Therapeutics Sub Inc filed Critical Gemini Therapeutics Sub Inc
Publication of MX2022000725A publication Critical patent/MX2022000725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se dan a conocer nuevos anticuerpos aislados, sintéticos o recombinantes y fragmentos de estos específicos del factor H, o ácidos nucleicos o vectores que codifican dichos anticuerpos y fragmentos. En el presente documento, se da a conocer además el uso de dichos anticuerpos, fragmentos, ácidos nucleicos o vectores para inhibir la activación del complemento y tratar de trastornos asociados con la activación del complemento.
MX2022000725A 2019-07-17 2020-07-17 Anticuerpos potenciadores del factor h y usos de estos. MX2022000725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875309P 2019-07-17 2019-07-17
PCT/US2020/042627 WO2021011903A1 (en) 2019-07-17 2020-07-17 Factor h potentiating antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2022000725A true MX2022000725A (es) 2022-04-26

Family

ID=74211270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000725A MX2022000725A (es) 2019-07-17 2020-07-17 Anticuerpos potenciadores del factor h y usos de estos.

Country Status (12)

Country Link
US (2) US11820814B2 (es)
EP (1) EP3999073A4 (es)
JP (1) JP2022541275A (es)
KR (1) KR20220057530A (es)
CN (1) CN114828886A (es)
AR (1) AR122286A1 (es)
AU (1) AU2020313981A1 (es)
BR (1) BR112022000739A2 (es)
CA (1) CA3147638A1 (es)
IL (1) IL289812A (es)
MX (1) MX2022000725A (es)
WO (1) WO2021011903A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
WO2006012621A2 (en) 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
CA2690124A1 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement-associated disorders
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
GB201318170D0 (en) * 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
WO2015067755A2 (en) 2013-11-07 2015-05-14 Novo Nordisk A/S Novel methods and antibodies for treating coagulapathy
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
EP3183266B1 (en) 2014-08-20 2019-05-29 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
EP3186277B1 (en) 2014-08-27 2020-10-07 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CN106928371B (zh) * 2015-12-31 2021-06-08 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
IL311675A (en) * 2016-04-04 2024-05-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
AU2017289214B2 (en) * 2016-06-28 2021-11-18 Universität Ulm Complement inhibitors and uses thereof
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2019139481A1 (en) * 2018-01-15 2019-07-18 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof

Also Published As

Publication number Publication date
JP2022541275A (ja) 2022-09-22
US11820814B2 (en) 2023-11-21
US20240336676A1 (en) 2024-10-10
EP3999073A4 (en) 2023-07-26
WO2021011903A1 (en) 2021-01-21
AU2020313981A8 (en) 2024-05-30
BR112022000739A2 (pt) 2022-04-12
IL289812A (en) 2022-03-01
CA3147638A1 (en) 2021-01-21
AU2020313981A1 (en) 2022-03-03
CN114828886A (zh) 2022-07-29
EP3999073A1 (en) 2022-05-25
AR122286A1 (es) 2022-08-31
TW202110893A (zh) 2021-03-16
KR20220057530A (ko) 2022-05-09
US20220372120A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2021004454A (es) Anticuerpos anti-sinucleina.
WO2018226985A3 (en) GUIDED COMBINATORY THERAPEUTIC ANTIBODY
MX2021002041A (es) Terapia génica para el tratamiento de galactosemia.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
ZA202110285B (en) Antibodies and methods of use
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
MX2022000725A (es) Anticuerpos potenciadores del factor h y usos de estos.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
CR20220107A (es) Proteínas de fusión nkg2d y sus usos
MX2022000263A (es) Nuevos antigenos y metodos contra el cancer.